新闻源 财富源

2019年10月21日 星期一

康缘药业(600557)公告正文

康缘药业:2016年第三季度报告

公告日期:2016-10-29

  江苏康缘药业股份有限公司 (股票代码:600557)           2016 年第三季度报告



公司代码:600557                                         公司简称:康缘药业




                 江苏康缘药业股份有限公司

                        2016 年第三季度报告




                                二〇一六年十月二十八日



                                            1 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)               2016 年第三季度报告




                                       目录
一、    重要提示.................................................................. 3

二、    公司主要财务数据和股东变化 ................................................ 3

三、    重要事项.................................................................. 6

四、    附录..................................................................... 10




                                          2 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                          2016 年第三季度报告




一、       重要提示

1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完

    整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

1.2 公司全体董事出席董事会审议季度报告。

1.3 公司负责人肖伟、主管会计工作负责人尹洪刚及会计机构负责人(会计主管人员)江锁

    成保证季度报告中财务报表的真实、准确、完整。

1.4 本公司第三季度报告未经审计。


二、       公司主要财务数据和股东变化

2.1 主要财务数据
                                                              单位:元 币种:人民币
                                                                            本报告期末比上
                                  本报告期末            上年度末
                                                                            年度末增减(%)
总资产                         4,573,203,760.92     4,304,503,018.18                    6.24
归属于上市公司股东的净资
                               3,062,540,019.71     2,810,636,242.02                    8.96

                               年初至报告期末       上年初至上年报告        比上年同期增减
                                 (1-9 月)           期末(1-9 月)              (%)
经营活动产生的现金流量净
                                 261,149,553.25       309,300,331.25                 -15.57

                               年初至报告期末       上年初至上年报告        比上年同期增减
                                 (1-9 月)           期末(1-9 月)            (%)
营业收入                       2,275,548,409.70     2,136,168,515.51                    6.52
归属于上市公司股东的净利
                                 292,992,018.14       288,286,593.05                    1.63

归属于上市公司股东的扣除
                                 277,575,829.58       278,510,175.70                   -0.34
非经常性损益的净利润
                                                                            减少 1.03 个百
加权平均净资产收益率(%)                    9.95              10.98
                                                                                      分点
基本每股收益(元/股)                        0.48                  0.47                 2.13
稀释每股收益(元/股)                        0.48                  0.47                 2.13




                                          3 / 23
         江苏康缘药业股份有限公司 (股票代码:600557)                              2016 年第三季度报告


         公司主要会计数据和财务指标的说明
         公司于 2016 年 6 月实施完成 2015 年度利润分配方案,总股本由 513,707,601 股变为

  616,449,121 股,根据《企业会计准则第 34 号—每股收益》应用指南的规定,本公司按照

  调整后的 616,449,121 股重新计算列报期间的每股收益。


  非经常性损益项目和金额
  √适用 □不适用
                                                                           单位:元 币种:人民币
                                                                   本期金额        年初至报告期末金
                            项目
                                                                 (7-9 月)         额(1-9 月)
非流动资产处置损益                                                    -667,946.63              -735,169.36
计入当期损益的政府补助,但与公司正常经营业务
密切相关,符合国家政策规定、按照一定标准定额                      16,281,597.61           19,505,060.25
或定量持续享受的政府补助除外
除上述各项之外的其他营业外收入和支出                              -2,576,448.68                -215,176.01
所得税影响额                                                      -1,970,982.32           -2,933,241.56
少数股东权益影响额(税后)                                            -133,429.96              -205,284.76
                            合计                                  10,932,790.02           15,416,188.56



  2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股

         情况表
                                                                                               单位:股
                  股东总数(户)                                                                     27,748
                                            前十名股东持股情况
                                                           持有有限售       质押或冻结情况
                                   期末持股数      比例
         股东名称(全称)                                  条件股份数                             股东性质
                                       量           (%)                    股份状态     数量
                                                                 量
                                                                                                 境内非国有
江苏康缘集团有限责任公司           169,416,462     27.48   162,269,684        无
                                                                                                    法人
                                                                                                 境内非国有
连云港康贝尔医疗器械有限公司        31,870,567      5.17                      无
                                                                                                    法人
中国工商银行股份有限公司-东方
红中国优势灵活配置混合型证券投      20,405,640      3.31                      无                    其他
资基金
中央汇金资产管理有限责任公司        18,280,080      2.97                      无                    其他
肖伟                                17,003,639      2.76                      无                 境内自然人
汇添富基金-工商银行-汇添富-
                                    11,945,196      1.94    11,945,196        无                    其他
康缘资产管理计划
博时基金-农业银行-博时中证金
                                     5,439,480      0.88                      无                    其他
融资产管理计划


                                                  4 / 23
         江苏康缘药业股份有限公司 (股票代码:600557)                           2016 年第三季度报告


工银瑞信基金-农业银行-工银瑞
                                     5,439,480       0.88                   无                 其他
信中证金融资产管理计划
易方达基金-农业银行-易方达中
                                     5,439,480       0.88                   无                 其他
证金融资产管理计划
嘉实基金-农业银行-嘉实中证金
                                     5,439,480       0.88                   无                 其他
融资产管理计划
中欧基金-农业银行-中欧中证金
                                     5,439,480       0.88                   无                 其他
融资产管理计划
大成基金-农业银行-大成中证金
                                     5,439,480       0.88                   无                 其他
融资产管理计划
                                     前十名无限售条件股东持股情况
                                     持有无限售条件流通股                  股份种类及数量
              股东名称
                                            的数量                  种类                    数量
连云港康贝尔医疗器械有限公司                     31,870,567     人民币普通股                31,870,567
中国工商银行股份有限公司-东方
红中国优势灵活配置混合型证券投                   20,405,640     人民币普通股                20,405,640
资基金
中央汇金资产管理有限责任公司                     18,280,080     人民币普通股                18,280,080
肖伟                                             17,003,639     人民币普通股                17,003,639
江苏康缘集团有限责任公司                         7,146,778      人民币普通股                 7,146,778
博时基金-农业银行-博时中证金
                                                 5,439,480      人民币普通股                 5,439,480
融资产管理计划
工银瑞信基金-农业银行-工银瑞
                                                 5,439,480      人民币普通股                 5,439,480
信中证金融资产管理计划
易方达基金-农业银行-易方达中
                                                 5,439,480      人民币普通股                 5,439,480
证金融资产管理计划
嘉实基金-农业银行-嘉实中证金
                                                 5,439,480      人民币普通股                 5,439,480
融资产管理计划
中欧基金-农业银行-中欧中证金
                                                 5,439,480      人民币普通股                 5,439,480
融资产管理计划
大成基金-农业银行-大成中证金
                                                 5,439,480      人民币普通股                 5,439,480
融资产管理计划
                                        前十大股东中,江苏康缘集团有限责任公司和肖伟先生存在关联关
                                    系,肖伟先生为江苏康缘集团有限责任公司第一大股东;汇添富基金-工
上述股东关联关系或一致行动的说      商银行-汇添富-康缘资产管理计划为江苏康缘集团有限责任公司一致
明                                  行动人。公司未知其他股东之间、其他股东与前十名无限售条件股东之间
                                    是否存在关联关系或一致行动人关系;公司未知其他前十名无限售条件股
                                    东之间是否存在关联关系或一致行动人关系。




     2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东

         持股情况表
     □适用 √不适用
                                                 5 / 23
       江苏康缘药业股份有限公司 (股票代码:600557)                      2016 年第三季度报告



   三、        重要事项

   3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
   √适用 □不适用

       3.1.1 截至报告期末,公司资产负债表项目大幅变动的原因分析

                                                                    单位:元   币种:人民币
                                                         变动比例
  项目名称           期末余额             期初余额                             变动原因
                                                           (%)
                                                                      主要系报告期内公司研发合
预付款项            46,021,813.97       28,675,087.40       60.49
                                                                      作预付款项增多所致
                                                                      主要系报告期内研究院装修
长期待摊费用         7,981,088.26         4,453,980.08      79.19
                                                                      改造计入长期待摊费用所致
                                                                      主要系报告期内偿还借款所
短期借款           130,139,874.71      343,000,000.00      -62.06
                                                                      致
                                                                      主要系报告期内应付票据到
应付票据                                86,900,000.00     -100.00
                                                                      期解付所致
                                                                      主要系报告期内新增客户预
预收款项            62,104,862.61       43,498,425.96       42.77
                                                                      付款项所致
                                                                      主要系报告期内子公司支付
应付股利                  8,437.50           24,375.00     -65.38
                                                                      现金股利所致
一年内到期的                                                          主要系报告期内偿还一年内
                    55,000,000.00       80,000,000.00      -31.25
非流动负债                                                            到期的非流动负债所致
                                                                      主要系报告期内发行超短期
其他流动负债       300,000,000.00
                                                                      融资券所致
                                                                      主要系报告期内长期借款重
长期借款                                45,000,000.00     -100.00     分类为一年内到期的非流动
                                                                      负债所致



           3.1.2 截至报告期末,公司利润表项目大幅变动的原因分析

                                                             单位:元      币种:人民币
                                                         变动比例
  项目名称           本期金额             上期金额                             变动原因
                                                           (%)
                                                                      主要系本报告期子公司增加
资产减值损失         2,715,522.95         1,402,013.25      93.69
                                                                      坏账准备所致
                                                                      主要系本报告期与收益相关
营业外收入          23,930,514.79       13,056,721.37       83.28     的政府补助确认为营业外收
                                                                      入较去年同期增加所致
                                                                      主要系本报告期对江苏阜宁
营业外支出           5,375,799.91         1,354,373.48     296.92
                                                                      自然灾害捐赠 300 万所致
                                              6 / 23
      江苏康缘药业股份有限公司 (股票代码:600557)                        2016 年第三季度报告


       3.1.3 截至报告期末,公司现金流量表项目大幅变动的原因分析

                                                                单位:元   币种:人民币
                                                             变动比例
  项目名称           本期金额          去年同期金额                             情况说明
                                                               (%)
购买商品、接
                                                                        主要系报告期内公司采购
受劳务支付的      540,593,384.71        348,979,177.00          54.91
                                                                        增加所致
现金
处置固定资
产、无形资产
                                                                        主要系报告期内收到处置
和其他长期资         7,321,818.63             76,010.00      9,532.70
                                                                        房产款项所致
产收回的现金
净额
收回投资收到
                   91,450,000.00                      0.00     不适用   主要系报告期内子公司支
的现金
                                                                        付及收回对理财产品的投
投资支付的现
                   88,479,800.00                      0.00     不适用   资款所致

取得借款收到
               2,136,370,000.00      1,236,574,286.67           72.77
的现金                                                                  主要系报告期内置换银行
偿还债务支付                                                            借款所致
               2,060,195,694.98      1,474,162,128.08           39.75
的现金
筹资活动产生
                                                                        主要系去年同期偿还银行
的现金流量净       16,840,255.87       -317,538,884.36         不适用
                                                                        借款远高于新增借款所致




   3.2 重要事项进展情况及其影响和解决方案的分析说明
   √适用 □不适用

       1、报告期内募集资金存放及使用情况的说明

       公司募集资金已于2015年度内使用完毕,详见公司于2016年4月16日在上海证券交易所

   网站(www.sse.com.cn)上刊登的《关于公司募集资金存放与实际使用情况的专项报告》。

       截止2015年12月31日,公司募集资金存储专户内余额37.33万元,已分别于2016年1月、

   4月用于补充流动资金,募投项目已全部完成,募集资金专户已注销,其中南京银行龙蟠路

   支行于2016年1月注销,招商银行连云港分行营业部于2016年5月注销。

       2、关于公司第六届董事会秘书任职情况的说明

       2016年9月5日,公司召开2016年第一次临时股东大会,审议并通过了《关于换届选举第

   六届董事会的议案》、《关于换届选举第六届监事会的议案》。(详见2016年9月6日刊登于



                                             7 / 23
       江苏康缘药业股份有限公司 (股票代码:600557)                          2016 年第三季度报告


  海证券交易所网站 www.sse.com.cn、《中国证券报》、《上海证券报》公告,公告编号:

  2016-026)。

       2016年9月5日,公司召开第六届董事会第一次会议,审议并通过了《关于聘任总经理、

  董事会秘书及证券事务代表的议案》。公司第六届董事会聘任尹洪刚先生为董事会秘书,任

  期与本届董事会相同。(详见2016年9月6日刊登于海证券交易所网站 www.sse.com.cn、《中

  国证券报》、《上海证券报》公告,公告编号:2016-027)。

       尹洪刚先生于2016年9月参加了上海证券交易所第七十七期董事会秘书资格培训,并取

  得上海证券交易所颁发的董事会秘书培训合格证书,且通过了上海证券交易所关于董事会秘

  书任职资格的审核,已正式履行董事会秘书职责。

       3、关于公司对外投资的情况说明

       2016年9月12日,公司召开第六届董事会第二次会议,审议并通过了《关于与南京华威

  医药科技开发有限公司签订合作投资协议进行对外投资的议案》,(详见2016年9月13日刊

  登于海证券交易所网站 www.sse.com.cn、《中国证券报》、《上海证券报》公告,公告编

  号:2016-030)。

       南京华威控股股东新疆百花村股份有限公司董事会亦于2016年9月12日审议通过上述事

  项。本次对外投资事项需等待新疆百花村股份有限公司股东大会审议通过。


  3.3 公司及持股 5%以上的股东承诺事项履行情况
  √适用 □不适用

                                                                                         是否   是否
承诺    承诺                                                                 承诺时间    有履   及时
                承诺方                       承诺内容
背景    类型                                                                  及期限     行期   严格
                                                                                          限    履行



                         公司控股股东江苏康缘集团有限责任公司在与本公司      承诺时间
与再
                江苏康   签署的《避免同业竞争股东协议书》中郑重承诺:目前, 为 2007 年
融资    解决
                缘集团   公司所有业务,康缘集团及其控股和实际控制下的其他     7 月 10
相关    同业                                                                              否     是
                有限责   企业均不涉及。康缘集团及其控股和实际控制下的其他    日,本承
的承    竞争
                任公司   企业与本公司及本公司控股、实际控制的企业间不存在    诺长期有
 诺
                         同业竞争的情形。                                       效




                                              8 / 23
       江苏康缘药业股份有限公司 (股票代码:600557)                          2016 年第三季度报告




                         江苏康缘集团有限责任公司将尽量减少与本公司之间
                         的关联交易。对于无法避免的任何业务往来或交易均应
                                                                             承诺时间
与再                     按照公平、公允和等价有偿的原则进行,交易价格应按
                江苏康                                                       为 2007 年
融资    解决             市场公认的合理价格确定,并按规定履行信息披露义
                缘集团                                                        7 月 10
相关    关联             务。康缘集团及其控股和实际控制下的其他企业与本公                 否    是
                有限责                                                       日,本承
的承    交易             司及本公司控股和实际控制下的其他企业就相互间关
                任公司                                                       诺长期有
诺                       联事务及交易所做出的任何约定及安排,均不妨碍对方
                                                                                效
                         为其自身利益、在市场同等竞争条件下与任何第三方进
                         行业务往来或交易。


与再                                                                         2014 年 12
                江苏康
融资                                                                         月 22 日
        股份    缘集团   康缘集团承诺认购本次发行的股票自发行结束之日起
相关                                                                         -2017 年     是    是
        限售    有限责   36 个月内不上市交易或转让。
的承                                                                         12 月 21
                任公司
诺                                                                              日




  3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变

       动的警示及原因说明
  □适用 √不适用



                                                       公司名称       江苏康缘药业股份有限公司
                                                       法定代表人     肖伟
                                                       日期           2016 年 10 月 28 日




                                              9 / 23
      江苏康缘药业股份有限公司 (股票代码:600557)                    2016 年第三季度报告



四、       附录

4.1     财务报表
                                 合并资产负债表
                               2016 年 9 月 30 日
编制单位:江苏康缘药业股份有限公司

                                              单位:元 币种:人民币 审计类型:未经审计
                   项目                               期末余额           年初余额
流动资产:
  货币资金                                            188,588,746.36     221,716,287.08
  结算备付金
  拆出资金
  以公允价值计量且其变动计入当期
损益的金融资产
  衍生金融资产
  应收票据                                            579,716,063.47     709,374,910.40
  应收账款                                       1,216,974,318.08        956,309,810.30
  预付款项                                             46,021,813.97      28,675,087.40
  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息
  应收股利
  其他应收款                                           55,379,591.91      50,786,318.62
  买入返售金融资产
  存货                                                178,217,176.79     187,850,105.20
  划分为持有待售的资产
  一年内到期的非流动资产
  其他流动资产                                         11,167,823.50      10,853,684.83
      流动资产合计                               2,276,065,534.08      2,165,566,203.83
非流动资产:
  发放贷款及垫款
  可供出售金融资产
  持有至到期投资
  长期应收款
  长期股权投资                                          3,979,348.70       3,978,529.97
  投资性房地产
  固定资产                                       1,741,994,319.09      1,622,791,154.66
  在建工程                                            108,915,613.65      92,325,802.64
  工程物资

                                            10 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                    2016 年第三季度报告


 固定资产清理
 生产性生物资产
 油气资产
 无形资产                                          316,531,169.12     295,929,763.23
 开发支出                                           18,000,000.00      18,000,000.00
 商誉                                               58,988,858.14      58,988,858.14
 长期待摊费用                                        7,981,088.26       4,453,980.08
 递延所得税资产                                      7,869,136.34      10,081,966.53
 其他非流动资产                                     32,878,693.54      32,386,759.10
   非流动资产合计                             2,297,138,226.84      2,138,936,814.35
      资产总计                                4,573,203,760.92      4,304,503,018.18
流动负债:
 短期借款                                          130,139,874.71     343,000,000.00
 向中央银行借款
 吸收存款及同业存放
 拆入资金
  以公允价值计量且其变动计入当期
损益的金融负债
 衍生金融负债
 应付票据                                                              86,900,000.00
 应付账款                                          229,869,914.31     253,566,639.80
 预收款项                                           62,104,862.61      43,498,425.96
 卖出回购金融资产款
 应付手续费及佣金
 应付职工薪酬                                        5,089,837.31       7,205,285.50
 应交税费                                           89,158,098.59      75,075,683.26
 应付利息                                            1,714,819.06       1,661,531.18
 应付股利                                               8,437.50            24,375.00
 其他应付款                                        476,196,888.19     393,885,068.87
 应付分保账款
 保险合同准备金
 代理买卖证券款
 代理承销证券款
 划分为持有待售的负债
 一年内到期的非流动负债                             55,000,000.00      80,000,000.00
 其他流动负债                                      300,000,000.00
   流动负债合计                               1,349,282,732.28      1,284,817,009.57
非流动负债:
 长期借款                                                              45,000,000.00
 应付债券
 其中:优先股
        永续债

                                         11 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                        2016 年第三季度报告


  长期应付款
  长期应付职工薪酬
  专项应付款                                         2,353,672.00           2,353,672.00
  预计负债
  递延收益                                          97,732,269.07         101,585,429.92
  递延所得税负债
  其他非流动负债
    非流动负债合计                                 100,085,941.07         148,939,101.92
      负债合计                                1,449,368,673.35          1,433,756,111.49
所有者权益
  股本                                             616,449,121.00         513,707,601.00
  其他权益工具
  其中:优先股
         永续债
  资本公积                                         520,433,141.68         520,433,141.68
  减:库存股
  其他综合收益                                        -210,973.83             -219,341.46
  专项储备
  盈余公积                                         237,552,889.89         237,552,889.89
  一般风险准备
  未分配利润                                  1,688,315,840.97          1,539,161,950.91
  归属于母公司所有者权益合计                  3,062,540,019.71          2,810,636,242.02
  少数股东权益                                      61,295,067.86          60,110,664.67
    所有者权益合计                            3,123,835,087.57          2,870,746,906.69
      负债和所有者权益总计                    4,573,203,760.92          4,304,503,018.18



法定代表人:肖伟          主管会计工作负责人:尹洪刚                会计机构负责人:江锁成




                                         12 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                    2016 年第三季度报告


                               母公司资产负债表
                               2016 年 9 月 30 日
编制单位:江苏康缘药业股份有限公司
                                       单位:元 币种:人民币 审计类型:未经审计
                 项目                              期末余额          年初余额
流动资产:
 货币资金                                          129,128,503.09     164,310,146.60
  以公允价值计量且其变动计入当期
损益的金融资产
 衍生金融资产
 应收票据                                          486,213,332.95     629,712,906.75
 应收账款                                     1,069,725,596.31        827,238,807.78
 预付款项                                           41,102,035.30      22,696,079.01
 应收利息
 应收股利                                            4,759,107.34       4,759,107.34
 其他应收款                                        347,228,624.80     251,689,188.08
 存货                                              156,151,706.49     163,064,614.72
 划分为持有待售的资产
 一年内到期的非流动资产
 其他流动资产
   流动资产合计                               2,234,308,906.28      2,063,470,850.28
非流动资产:
 可供出售金融资产
 持有至到期投资
 长期应收款
 长期股权投资                                      224,533,431.37     189,532,612.64
 投资性房地产
 固定资产                                     1,452,309,023.09      1,375,363,472.18
 在建工程                                          100,868,259.02      43,025,950.72
 工程物资
 固定资产清理
 生产性生物资产
 油气资产
 无形资产                                          250,610,718.37     226,884,874.59
 开发支出                                           18,000,000.00      18,000,000.00
 商誉
 长期待摊费用                                        7,204,495.58       3,457,147.23
 递延所得税资产                                      3,893,660.91       5,977,513.48
 其他非流动资产                                     27,133,697.75      19,699,254.78
   非流动资产合计                             2,084,553,286.09      1,881,940,825.62
      资产总计                                4,318,862,192.37      3,945,411,675.90
流动负债:

                                         13 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                    2016 年第三季度报告


 短期借款                                          130,139,874.71     283,000,000.00
  以公允价值计量且其变动计入当期
损益的金融负债
 衍生金融负债
 应付票据                                                              86,900,000.00
 应付账款                                          200,645,276.81     192,880,487.28
 预收款项                                           36,223,408.91      18,505,611.15
 应付职工薪酬                                        2,799,183.52       4,610,831.32
 应交税费                                           84,008,549.01      63,923,402.50
 应付利息                                            1,714,819.06          657,197.84
 应付股利
 其他应付款                                        394,471,705.81     313,867,062.13
 划分为持有待售的负债
 一年内到期的非流动负债                             55,000,000.00      80,000,000.00
 其他流动负债                                      300,000,000.00
   流动负债合计                               1,205,002,817.83      1,044,344,592.22
非流动负债:
 长期借款                                                              45,000,000.00
 应付债券
 其中:优先股
        永续债
 长期应付款
 长期应付职工薪酬
 专项应付款                                          2,353,672.00       2,353,672.00
 预计负债
 递延收益                                           74,835,052.47      78,244,064.66
 递延所得税负债
 其他非流动负债
   非流动负债合计                                  77,188,724.47      125,597,736.66
      负债合计                                1,282,191,542.30      1,169,942,328.88
所有者权益:
 股本                                              616,449,121.00     513,707,601.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                          520,570,073.21     520,570,073.21
 减:库存股
 其他综合收益
 专项储备
 盈余公积                                          235,745,729.33     235,745,729.33
 未分配利润                                   1,663,905,726.53      1,505,445,943.48
   所有者权益合计                             3,036,670,650.07      2,775,469,347.02

                                         14 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                     2016 年第三季度报告


      负债和所有者权益总计                    4,318,862,192.37       3,945,411,675.90



法定代表人:肖伟            主管会计工作负责人:尹洪刚           会计机构负责人:江锁成




                                         15 / 23
       江苏康缘药业股份有限公司 (股票代码:600557)                      2016 年第三季度报告


                                           合并利润表
                                         2016 年 1—9 月
  编制单位:江苏康缘药业股份有限公司
                                               单位:元 币种:人民币 审计类型:未经审计
                       本期金额           上期金额         年初至报告期期末   上年年初至报告期
       项目
                       (7-9 月)         (7-9 月)       金额 (1-9 月)    期末金额(1-9 月)
一、营业总收入      772,961,378.52     708,831,273.66      2,275,548,409.70   2,136,168,515.51
其中:营业收入      772,961,378.52     708,831,273.66      2,275,548,409.70   2,136,168,515.51
       利息收入                 0.00               0.00
       已赚保费                 0.00               0.00
      手续费及
                                0.00               0.00
佣金收入
二、营业总成本      667,328,971.86     600,829,003.67      1,948,126,275.90   1,805,691,257.61
其中:营业成本      185,059,928.60     183,083,560.48        562,552,280.05     553,300,541.94
       利息支出                 0.00               0.00
      手续费及
                                0.00               0.00
佣金支出
       退保金                   0.00               0.00
       赔付支出
                                0.00               0.00
净额
      提取保险
                                0.00               0.00
合同准备金净额
       保单红利
                                0.00               0.00
支出
       分保费用                 0.00               0.00
      营业税金
                      13,260,240.53      11,229,514.74        37,910,959.54      34,951,559.70
及附加
       销售费用     357,004,262.76     317,038,445.36      1,003,291,291.94     913,264,704.35
       管理费用       98,428,986.89      77,775,887.62       307,418,175.01     269,563,515.02
       财务费用       10,301,561.73      10,951,887.34        34,238,046.41      33,208,923.35
       资产减值
                       3,273,991.35         749,708.13         2,715,522.95       1,402,013.25
损失
  加:公允价值变
动收益(损失以                  0.00               0.00
“-”号填列)
      投资收益
(损失以“-”号         489,051.01        -606,579.76           489,869.74        -604,229.60
填列)
      其中:对联
营企业和合营企                 0.00                0.00              818.73            2,350.16
业的投资收益
      汇兑收益
                                0.00               0.00
(损失以“-”号
                                             16 / 23
         江苏康缘药业股份有限公司 (股票代码:600557)                   2016 年第三季度报告


填列)
三、营业利润(亏
                   106,121,457.67        107,395,690.23     327,912,003.54    329,873,028.30
损以“-”号填列)
  加:营业外收入        18,345,779.48       8,770,720.82     23,930,514.79     13,056,721.37
      其中:非流
                                  0.00               0.00
动资产处置利得
  减:营业外支出         5,308,577.18         403,428.86      5,375,799.91       1,354,373.48
      其中:非流
                                  0.00               0.00
动资产处置损失
四、利润总额(亏
损总额以“-”        119,158,659.97     115,762,982.19     346,466,718.42    341,575,376.19
号填列)
  减:所得税费用        17,994,797.41      17,177,449.45     52,290,297.09     51,287,552.11
五、净利润(净亏
损以“-”号填        101,163,862.56       98,585,532.74    294,176,421.33    290,287,824.08
列)
  归属于母公司
                      102,023,723.25       98,370,608.88    292,992,018.14    288,286,593.05
所有者的净利润
  少数股东损益            -859,860.69         214,923.86      1,184,403.19       2,001,231.03
六、其他综合收益
                             2,385.67           1,456.25         8,367.63               709.38
的税后净额
  归属母公司所
有者的其他综合                2,385.67           1,456.25         8,367.63              709.38
收益的税后净额
    (一)以后不
能重分类进损益                    0.00               0.00
的其他综合收益
    (二)以后将
重分类进损益的                2,385.67           1,456.25         8,367.63              709.38
其他综合收益
      1. 权 益 法
下在被投资单位
以后将重分类进
损益的其他综合
收益中享有的份

      2. 可 供 出
售金融资产公允
价值变动损益
      3. 持 有 至
到期投资重分类
为可供出售金融
资产损益

                                               17 / 23
      江苏康缘药业股份有限公司 (股票代码:600557)                    2016 年第三季度报告


      4. 现 金 流
量套期损益的有
效部分
      5. 外 币 财
                           2,385.67           1,456.25          8,367.63              709.38
务报表折算差额
      6.其他
  归属于少数股
东的其他综合收
益的税后净额
七、综合收益总额    101,166,248.23      98,586,988.99     294,184,788.96    290,288,533.46
  归属于母公司
所有者的综合收      102,026,108.92      98,372,065.13     293,000,385.77    288,287,302.43
益总额
   归属于少数股
东的综合收益总         -859,860.69         214,923.86       1,184,403.19       2,001,231.03

八、每股收益:
  (一)基本每股
                               0.17               0.16              0.48                0.47
收益(元/股)
  (二)稀释每股
                               0.17               0.16              0.48                0.47
收益(元/股)



  法定代表人:肖伟           主管会计工作负责人:尹洪刚          会计机构负责人:江锁成




                                            18 / 23
        江苏康缘药业股份有限公司 (股票代码:600557)                        2016 年第三季度报告


                                       母公司利润表
                                     2016 年 1—9 月
     编制单位:江苏康缘药业股份有限公司
                                           单位:元 币种:人民币 审计类型:未经审计
                       本期金额          上期金额    年初至报告期期末 上年年初至报告期
       项目
                       (7-9 月)       (7-9 月)     金额(1-9 月)  期末金额(1-9 月)
一、营业收入          703,010,766.30     601,584,547.81        1,975,632,127.69   1,816,886,255.63
  减:营业成本        169,446,009.83     157,232,668.36          494,395,789.39     479,337,325.71
       营业税金及
                        12,159,995.90      9,088,686.11           32,566,031.58      29,436,335.98
附加
       销售费用       313,292,921.37     250,809,236.66          825,780,693.15     727,491,713.26
       管理费用         88,519,573.70     67,789,199.77          269,811,399.12     232,457,707.71
       财务费用          8,268,667.86      8,688,393.18           26,127,508.32      21,834,311.04
       资产减值损
                         1,571,125.97         864,323.10         -12,804,224.89       1,325,642.91

  加:公允价值变
动收益(损失以                    0.00                  0.00
“-”号填列)
      投 资 收 益
(损失以“-”号                  0.00       -469,084.07                 818.73        -466,733.91
填列)
      其中:对联
营企业和合营企业                     0                    0              818.73           2,350.16
的投资收益
二、营业利润(亏损
                      109,752,471.67     106,642,956.56          339,755,749.75     324,536,485.11
以“-”号填列)
  加:营业外收入        17,526,312.03      8,615,720.81           21,174,534.93      12,888,921.36
      其中:非流
                                  0.00                  0.00
动资产处置利得
  减:营业外支出         5,146,637.45         399,309.47           5,285,683.35       1,349,004.09
      其中:非流
                                  0.00                  0.00
动资产处置损失
三、利润总额(亏损
                     122,132,146.25      114,859,367.90          355,644,601.33     336,076,402.38
总额以“-”号填列)
        减:所得税
                        18,319,821.94     17,099,256.72           53,346,690.20      49,777,264.19
费用
四、净利润(净亏损
                      103,812,324.31      97,760,111.18          302,297,911.13     286,299,138.19
以“-”号填列)
五、其他综合收益的
税后净额
六、综合收益总额      103,812,324.31      97,760,111.18          302,297,911.13     286,299,138.19

     法定代表人:肖伟           主管会计工作负责人:尹洪刚              会计机构负责人:江锁成

                                              19 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                        2016 年第三季度报告


                                合并现金流量表
                                2016 年 1—9 月
编制单位:江苏康缘药业股份有限公司
                                     单位:元 币种:人民币 审计类型:未经审计
                                         年初至报告期期末金额       上年年初至报告期期末
                项目
                                               (1-9 月)               金额(1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                2,491,530,607.32          2,173,303,345.48
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额
  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入
当期损益的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还                                     1,846,336.53
  收到其他与经营活动有关的现金                      92,581,957.62         104,017,397.23
    经营活动现金流入小计                      2,585,958,901.47          2,277,320,742.71
  购买商品、接受劳务支付的现金                     540,593,384.71         348,979,177.00
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                   264,487,024.26         255,274,197.35
  支付的各项税费                                   416,949,815.77         367,231,319.68
  支付其他与经营活动有关的现金                1,102,779,123.48            996,535,717.43
    经营活动现金流出小计                      2,324,809,348.22          1,968,020,411.46
      经营活动产生的现金流量净额                   261,149,553.25         309,300,331.25
二、投资活动产生的现金流量:
  收回投资收到的现金                                91,450,000.00
  取得投资收益收到的现金                               178,822.48
  处置固定资产、无形资产和其他长期
                                                     7,321,818.63               76,010.00
资产收回的现金净额
  处置子公司及其他营业单位收到的
现金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                            98,950,641.11               76,010.00

                                         20 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                          2016 年第三季度报告


  购建固定资产、无形资产和其他长期
                                                   321,594,488.92           280,712,561.70
资产支付的现金
  投资支付的现金                                    88,479,800.00
  质押贷款净增加额
  取得子公司及其他营业单位支付的
现金净额
  支付其他与投资活动有关的现金                                                        135.54
    投资活动现金流出小计                           410,074,288.92           280,712,697.24
      投资活动产生的现金流量净额               -311,123,647.81             -280,636,687.24
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  其中:子公司吸收少数股东投资收到
的现金
  取得借款收到的现金                          2,136,370,000.00            1,236,574,286.67
  发行债券收到的现金
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                      2,136,370,000.00            1,236,574,286.67
  偿还债务支付的现金                          2,060,195,694.98            1,474,162,128.08
  分配股利、利润或偿付利息支付的现
                                                    59,334,049.15            79,951,042.95

  其中:子公司支付给少数股东的股
利、利润
  支付其他与筹资活动有关的现金
    筹资活动现金流出小计                      2,119,529,744.13            1,554,113,171.03
      筹资活动产生的现金流量净额                    16,840,255.87          -317,538,884.36
四、汇率变动对现金及现金等价物的影
                                                         6,297.97                 19,798.09

五、现金及现金等价物净增加额                       -33,127,540.72          -288,855,442.26
  加:期初现金及现金等价物余额                     221,716,287.08           553,542,219.35
六、期末现金及现金等价物余额                       188,588,746.36           264,686,777.09



法定代表人:肖伟           主管会计工作负责人:尹洪刚               会计机构负责人:江锁成




                                         21 / 23
   江苏康缘药业股份有限公司 (股票代码:600557)                        2016 年第三季度报告


                                母公司现金流量表
                                  2016 年 1—9 月
编制单位:江苏康缘药业股份有限公司
                                       单位:元 币种:人民币 审计类型:未经审计
                                         年初至报告期期末金额       上年年初至报告期期末
                项目
                                               (1-9 月)               金额(1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                2,207,989,800.82          1,818,927,099.36
  收到的税费返还
  收到其他与经营活动有关的现金                     150,873,542.28          59,825,958.57
    经营活动现金流入小计                      2,358,863,343.10          1,878,753,057.93
  购买商品、接受劳务支付的现金                     488,438,439.45         296,586,412.88
  支付给职工以及为职工支付的现金                   215,552,952.91         203,620,576.31
  支付的各项税费                                   359,041,576.80         307,855,671.51
  支付其他与经营活动有关的现金                1,040,325,645.41            848,188,175.96
    经营活动现金流出小计                      2,103,358,614.57          1,656,250,836.66
  经营活动产生的现金流量净额                       255,504,728.53         222,502,221.27
二、投资活动产生的现金流量:
  收回投资收到的现金                                                        1,713,028.93
  取得投资收益收到的现金
  处置固定资产、无形资产和其他长期
                                                     7,317,288.63               75,000.00
资产收回的现金净额
  处置子公司及其他营业单位收到的
现金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                             7,317,288.63           1,788,028.93
  购建固定资产、无形资产和其他长期
                                                   284,207,360.90         265,919,528.29
资产支付的现金
  投资支付的现金                                    35,729,800.00
  取得子公司及其他营业单位支付的
现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                           319,937,160.90         265,919,528.29
      投资活动产生的现金流量净额               -312,619,872.27           -264,131,499.36
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                          1,886,370,000.00            900,574,286.67
  收到其他与筹资活动有关的现金
    筹资活动现金流入小计                      1,886,370,000.00            900,574,286.67
  偿还债务支付的现金                          1,810,195,694.98            948,162,128.08
  分配股利、利润或偿付利息支付的现
                                                    54,240,804.79          68,772,267.34

  支付其他与筹资活动有关的现金                                            120,000,000.00
                                         22 / 23
      江苏康缘药业股份有限公司 (股票代码:600557)                         2016 年第三季度报告


      筹资活动现金流出小计                       1,864,436,499.77          1,136,934,395.42
         筹资活动产生的现金流量净额                   21,933,500.23          -236,360,108.75
四、汇率变动对现金及现金等价物的影

五、现金及现金等价物净增加额                          -35,181,643.51         -277,989,386.84
  加:期初现金及现金等价物余额                        164,310,146.60          480,293,517.16
六、期末现金及现金等价物余额                          129,128,503.09          202,304,130.32



法定代表人:肖伟              主管会计工作负责人:尹洪刚               会计机构负责人:江锁成




4.2     审计报告
□适用 √不适用




                                            23 / 23